US equities |
MU $1,088.00 ▲+0.00% SNDK $1,692.42 ▲+0.00% NVDA $237.47 ▲+0.00% INTC $113.12 ▲+0.00% PLTR $194.12 ▲+0.00% SPCX $167.60 ▲+0.00% AMD $645.86 ▲+0.00% MSTR $153.37 ▲+0.00%
FinancialContent

Articles published by Teva Pharmaceutical Industries Ltd

< Previous 1 2 3 4 Next >
News headline image
Teva to Present at the Goldman Sachs Global Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva to Present at the BofA Securities Health Care Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Releases Q1 2026 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva to Present at the Upcoming Investor Conferences in March
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers RPRX TEVA
News headline image
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers ALVO TEVA
News headline image
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Releases Q4 2025 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
< Previous 1 2 3 4 Next >